| 000 | 01568 a2200445 4500 | ||
|---|---|---|---|
| 005 | 20250514002856.0 | ||
| 264 | 0 | _c20010726 | |
| 008 | 200107s 0 0 eng d | ||
| 022 | _a0950-9232 | ||
| 024 | 7 |
_a10.1038/sj.onc.1204092 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aBearss, D J | |
| 245 | 0 | 0 |
_aTelomere maintenance mechanisms as a target for drug development. _h[electronic resource] |
| 260 |
_bOncogene _cDec 2000 |
||
| 300 |
_a6632-41 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, U.S. Gov't, P.H.S.; Review | ||
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aAnthracenes _xpharmacology |
| 650 | 0 | 4 |
_aAntineoplastic Agents _xpharmacology |
| 650 | 0 | 4 | _aDrug Delivery Systems |
| 650 | 0 | 4 | _aDrug Design |
| 650 | 0 | 4 |
_aGlycoside Hydrolases _xmetabolism |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aNeoplasms _xenzymology |
| 650 | 0 | 4 |
_aOligonucleotides, Antisense _xtherapeutic use |
| 650 | 0 | 4 |
_aPerylene _xanalogs & derivatives |
| 650 | 0 | 4 |
_aPiperidines _xpharmacology |
| 650 | 0 | 4 |
_aPoly(ADP-ribose) Polymerases _xmetabolism |
| 650 | 0 | 4 | _aRNA |
| 650 | 0 | 4 | _aRNA, Long Noncoding |
| 650 | 0 | 4 |
_aRNA, Untranslated _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aReverse Transcriptase Inhibitors _xpharmacology |
| 650 | 0 | 4 | _aTankyrases |
| 650 | 0 | 4 |
_aTelomerase _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aTelomere _xchemistry |
| 700 | 1 | _aHurley, L H | |
| 700 | 1 | _aVon Hoff, D D | |
| 773 | 0 |
_tOncogene _gvol. 19 _gno. 56 _gp. 6632-41 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1038/sj.onc.1204092 _zAvailable from publisher's website |
| 999 |
_c11356106 _d11356106 |
||